UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 41,428 Shares of Boston Scientific Corporation $BSX

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 0.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,936,957 shares of the medical equipment provider's stock after selling 41,428 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.74% of Boston Scientific worth $1,042,839,000 at the end of the most recent reporting period.Get Boston Scientific alerts:Why These Three Big Buybacks Are Sending Very Different Signals to InvestorsSeveral other hedge funds also recently modified their holdings of BSX. Brighton Jones LLC increased its stake in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after acquiring an additional 226 shares in the last quarter. FWL Investment Management LLC bought a new stake in shares of Boston Scientific in the 2nd quarter valued at $26,000. Main Street Financial Solutions LLC increased its stake in shares of Boston Scientific by 35.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider's stock valued at $812,000 after acquiring an additional 1,971 shares in the last quarter. Ieq Capital LLC increased its stake in shares of Boston Scientific by 97.0% in the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider's stock valued at $13,275,000 after acquiring an additional 60,860 shares in the last quarter. Finally, HUB Investment Partners LLC increased its stake in shares of Boston Scientific by 56.2% in the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider's stock valued at $763,000 after acquiring an additional 2,556 shares in the last quarter. Institutional investors own 89.07% of the company's stock. Insider Activity at Boston ScientificIn related news, Director Edward J. Ludwig purchased 3,580 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the transaction, the director owned 25,359 shares of the company's stock, valued at $1,437,348.12. This represents a 16.44% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David C. Habiger purchased 2,250 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the transaction, the director directly owned 13,878 shares in the company, valued at $776,057.76. The trade was a 19.35% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders purchased 9,800 shares of company stock valued at $554,012. 0.34% of the stock is owned by insiders. Wall Street Analyst Weigh InWhy Boston Scientific's Big Dip Could Be a Bigger OpportunityA number of equities analysts recently issued reports on the company. Leerink Partners cut their target price on Boston Scientific from $87.00 to $74.00 and set an "outperform" rating on the stock in a report on Thursday, May 28th. Raymond James Financial reiterated an "outperform" rating and issued a $88.00 target price (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. Mizuho cut their target price on Boston Scientific from $115.00 to $90.00 and set an "outperform" rating on the stock in a report on Monday, April 13th. Piper Sandler reiterated an "overweight" rating and issued a $65.00 target price on shares of Boston Scientific in a report on Friday. Finally, Stifel Nicolaus set a $75.00 target price on Boston Scientific in a report on Wednesday, May 27th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Boston Scientific currently has an average rating of "Moderate Buy" and a consensus target price of $85.08.View Our Latest Report on Boston ScientificKey Headlines Impacting Boston ScientificBeware the Death Cross: 3 Stocks Triggering This Spooky SignalHere are the key news stories impacting Boston Scientific this week: Positive Sentiment: Analysts remain constructive on Boston Scientific, with one note saying the stock could still rise sharply from current levels despite this year’s de-rating. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months Positive Sentiment: Boston Scientific may benefit from Penumbra’s newly FDA-cleared stroke thrombectomy platform, which one analyst said could add about $100 million in incremental revenue over time. Penumbra’s FDA nod for clot removal tech a win for Boston Scientific Positive Sentiment: BTIG stayed bullish on BSX, pointing to valuation and substantial upside potential despite the recent decline in the share price. BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock Positive Sentiment: Boston Scientific reported strong catheter study results, which could support confidence in its clinical pipeline and product adoption. Boston Scientific Corp (BSX) Reports Strong Success Rates From Catheter Study Neutral Sentiment: Erste Group trimmed its FY2026 and FY2027 EPS estimates slightly, a modest negative on expectations but not a major change to the broader consensus. Boston Scientific Corporation NYSE: BSX - Free Report Negative Sentiment: Boston Scientific has repeatedly walked back full-year 2026 guidance, and that ongoing uncertainty is pressuring the stock and contributing to its decline. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months Negative Sentiment: One Seeking Alpha piece argues the market is treating BSX like a “broken compounder,” reflecting skepticism that has weighed on the shares. Boston Scientific: The Market Is Pricing A Broken Compounder-We See A Reset One Boston Scientific Trading Down 0.7%NYSE BSX opened at $46.83 on Friday. The firm has a market capitalization of $69.60 billion, a P/E ratio of 19.59, a PEG ratio of 0.89 and a beta of 0.56. The business has a fifty day simple moving average of $56.37 and a 200 day simple moving average of $74.95. Boston Scientific Corporation has a 12 month low of $45.99 and a 12 month high of $109.50. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts' consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.Boston Scientific's quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, analysts predict that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year. Boston Scientific announced that its Board of Directors has initiated a stock repurchase plan on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback plans are often an indication that the company's board of directors believes its stock is undervalued. Boston Scientific Company Profile (Free Report)Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery. Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.Further ReadingFive stocks we like better than Boston ScientificSpaceX Rings the Bell and Shatters Every RecordAdobe Stock Just Got Cheaper—Is Wall Street Missing the Story?3 Dividend Stocks Under $50 That Pay You to Wait Out InflationThe 127-Gigawatt Problem: Why AI Needs Its Own PowerWant to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Boston Scientific Right Now?Before you consider Boston Scientific, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.While Boston Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here